While our finding of a FOXA1-GR dependency for a subset of NSCLC nominates an intriguing new therapeutic approach for this disease, it is unlikely that GR-targeted therapy will be efficacious as a single agent in a tumor type where nearly 60% of patients harbor genomic alterations hyperactivating RAS and EGFR. This evidence concerns the gene FOXA1 and neoplasm.